1,054
Views
14
CrossRef citations to date
0
Altmetric
Letters to the Editor

Central Serous Chorioretinopathy Associated with Topical Latanoprost Therapy

, MD, , MD, , MD, , MD & , MD
Pages 453-455 | Received 09 Dec 2010, Accepted 30 Aug 2011, Published online: 22 Nov 2011

Figures & data

FIGURE 1  (A) At presentation, funduscopic examination of right eye shows evidence of an area of indistinct serous elevation with superiotemporal yellowish pigmentation. (Arrows delineate the limits of serous retinal detachment.) (B) Midphase fluorescein angiography (FA) shows progressive enlargement of a focal leakage point superonasal to the fovea and associated retinal pigment epithelial changes. (C) Four weeks after stopping the latanoprost therapy, FA showing resolution of leakage.

FIGURE 1  (A) At presentation, funduscopic examination of right eye shows evidence of an area of indistinct serous elevation with superiotemporal yellowish pigmentation. (Arrows delineate the limits of serous retinal detachment.) (B) Midphase fluorescein angiography (FA) shows progressive enlargement of a focal leakage point superonasal to the fovea and associated retinal pigment epithelial changes. (C) Four weeks after stopping the latanoprost therapy, FA showing resolution of leakage.

FIGURE 2  (A) Baseline horizontal OCT scan shows serous retinal detachment with a few irregularities on outer neurosensory retina related to central serous chorioretinopathy (CSC). (B) After stopping the therapy, significant resolution of submacular fluid was observed in same section of OCT scan with marked decrease of foveal thickening from 345 to 198 μm and visual acuity improved to 20/20.

FIGURE 2  (A) Baseline horizontal OCT scan shows serous retinal detachment with a few irregularities on outer neurosensory retina related to central serous chorioretinopathy (CSC). (B) After stopping the therapy, significant resolution of submacular fluid was observed in same section of OCT scan with marked decrease of foveal thickening from 345 to 198 μm and visual acuity improved to 20/20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.